Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients

BACKGROUND: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of nasal septum perforations have been reported. We report our experience of nasal perforation in breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Mailliez, A, Baldini, C, Van, J T, Servent, V, Mallet, Y, Bonneterre, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966623/
https://www.ncbi.nlm.nih.gov/pubmed/20736943
http://dx.doi.org/10.1038/sj.bjc.6605828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966623/
https://www.ncbi.nlm.nih.gov/pubmed/20736943
http://dx.doi.org/10.1038/sj.bjc.6605828

Ejemplares similares